87 related articles for article (PubMed ID: 7746737)
1. Role of DNA ploidy and ERB-B2 oncogene expression in the prognosis of endometrial carcinoma.
Ferrara F; De Santis L; Mangili F; Sassi I; Luchini S; Mandelli C; Santambrogio G; Cantaboni A
Pathol Res Pract; 1994 Nov; 190(11):1039-43. PubMed ID: 7746737
[TBL] [Abstract][Full Text] [Related]
2. Role of DNA ploidy analysis in endometrial adenocarcinoma.
Jhala DN; Atkinson BF; Balsara GR; Hernandez E; Jhala NC
Ann Diagn Pathol; 2001 Oct; 5(5):267-73. PubMed ID: 11598854
[TBL] [Abstract][Full Text] [Related]
3. [Prognostic evaluation of endometrial carcinoma by DNA content and histologic factors].
Shimizu K
Nihon Sanka Fujinka Gakkai Zasshi; 1995 Apr; 47(4):413-8. PubMed ID: 7730696
[TBL] [Abstract][Full Text] [Related]
4. DNA ploidy analysis of endometrial adenocarcinoma using a flow cytometry from paraffin-embedded tissues.
Takahashi Y
Nihon Sanka Fujinka Gakkai Zasshi; 1990 Oct; 42(10):1339-44. PubMed ID: 1700035
[TBL] [Abstract][Full Text] [Related]
5. Effect of deoxyribonucleic acid ploidy status on survival of patients with carcinoma of the endometrium.
Dyas CH; Simmons TK; Ellis CN; Austin JM; Partridge EE; Kilgore LC; Reading C; Nelson K; Blakemore WS
Surg Gynecol Obstet; 1992 Feb; 174(2):133-6. PubMed ID: 1734571
[TBL] [Abstract][Full Text] [Related]
6. DNA ploidy status: its impact on early-stage endometrial adenocarcinoma.
Goodman A; Bell DA; Rice LW
Gynecol Oncol; 1993 Dec; 51(3):355-61. PubMed ID: 8112645
[TBL] [Abstract][Full Text] [Related]
7. Effects of tamoxifen on steroid hormone receptors and hormone concentration and the results of DNA analysis by flow cytometry in endometrial carcinoma.
Nola M; Jukić S; Ilić-Forko J; Babić D; Uzarević B; Petrovecki M; Suchanek E; Skrablin S; Dotlić S; Marusić M
Gynecol Oncol; 1999 Mar; 72(3):331-6. PubMed ID: 10053103
[TBL] [Abstract][Full Text] [Related]
8. DNA flow cytometric analysis of clinical stage I endometrial carcinomas with lymph node metastases.
Coleman RL; Schink JC; Miller DS; Bauer KD; August CZ; Rademaker AW; Lurain JR
Gynecol Oncol; 1993 Jul; 50(1):20-4. PubMed ID: 8349159
[TBL] [Abstract][Full Text] [Related]
9. [A study on DNA content and cell cycle phase analysis in endometrial carcinoma].
Xue F; Jiao S; Zhao F
Zhonghua Fu Chan Ke Za Zhi; 1996 Apr; 31(4):216-9. PubMed ID: 8758776
[TBL] [Abstract][Full Text] [Related]
10. Ten-year results of a prospective study on the prognostic role of ploidy in endometrial carcinoma: dNA aneuploidy identifies high-risk cases among the so-called 'low-risk' patients with well and moderately differentiated tumors.
Susini T; Amunni G; Molino C; Carriero C; Rapi S; Branconi F; Marchionni M; Taddei G; Scarselli G
Cancer; 2007 Mar; 109(5):882-90. PubMed ID: 17262824
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of DNA ploidy in endometrial cancer.
Ikeda M; Watanabe Y; Nanjoh T; Noda K
Gynecol Oncol; 1993 Jul; 50(1):25-9. PubMed ID: 8349160
[TBL] [Abstract][Full Text] [Related]
12. Association of steroid hormone receptor content and flow cytometric DNA ploidy in endometrial carcinoma.
Grénman SE; Klemi P; Toikkanen S; Irjala K; Laippala P; Vähä-Eskeli K; Mäenpää J; Salmi T
Ann Chir Gynaecol Suppl; 1994; 208():10-4. PubMed ID: 8092757
[TBL] [Abstract][Full Text] [Related]
13. Prospective multicenter validation confirms the prognostic superiority of the endometrial carcinoma prognostic index in international Federation of gynecology and obstetrics stage 1 and 2 endometrial carcinoma.
Baak JP; Snijders W; van Diermen B; van Diest PJ; Diepenhorst FW; Benraadt J
J Clin Oncol; 2003 Nov; 21(22):4214-21. PubMed ID: 14615450
[TBL] [Abstract][Full Text] [Related]
14. Endometrial carcinomas--flow cytometric DNA content and S-phase values.
Jacobsen M; Jakobsen A; Nedergaard L; Andersen JE; Nielsen K
Pathol Res Pract; 1997; 193(4):283-90. PubMed ID: 9258954
[TBL] [Abstract][Full Text] [Related]
15. Identification of HER-2/neu oncogene amplification by fluorescence in situ hybridization in stage I endometrial carcinoma.
Riben MW; Malfetano JH; Nazeer T; Muraca PJ; Ambros RA; Ross JS
Mod Pathol; 1997 Aug; 10(8):823-31. PubMed ID: 9267826
[TBL] [Abstract][Full Text] [Related]
16. Flow cytometric determination of ploidy in prostatic adenocarcinoma and its relation to clinical outcome.
Blatstein LM; Ginsberg PC; Daskal I; Finkelstein LH
J Am Osteopath Assoc; 1993 Apr; 93(4):463-8, 471-2. PubMed ID: 8478220
[TBL] [Abstract][Full Text] [Related]
17. [Usefulness of DNA ploidy, AgNORs, PCNA and c-erbB-2 as predictors of prognosis in patients with renal cell carcinoma].
Tamaki M; Maeda S; Deguchi T; Kawada Y
Hinyokika Kiyo; 1997 Oct; 43(10):697-702. PubMed ID: 9395903
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of DNA ploidy and S-phase fraction in endometrial cancer stage I and II: a prospective 5-year survival study.
Friberg LG; Norén H; Delle U
Gynecol Oncol; 1994 Apr; 53(1):64-9. PubMed ID: 8175025
[TBL] [Abstract][Full Text] [Related]
19. Low-risk endometrial carcinoma: assessment of a treatment policy based on tumor ploidy and identification of additional prognostic indicators.
Lim P; Aquino-Parsons CF; Wong F; Dupuis B; Phillips D; Zhou C; Gilks CB
Gynecol Oncol; 1999 May; 73(2):191-5. PubMed ID: 10329033
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of DNA ploidy and S-phase fraction in stage I endometrial carcinoma.
Pfisterer J; Kommoss F; Sauerbrei W; Rendl I; Kiechle M; Kleine W; Pfleiderer A
Gynecol Oncol; 1995 Aug; 58(2):149-56. PubMed ID: 7622098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
